nasdaq-mynz-mainzbiomed.png
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
October 11, 2023 08:01 ET | Mainz BioMed NV
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
nasdaq-mynz-mainzbiomed.png
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit 
October 05, 2023 08:01 ET | Mainz BioMed NV
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
nasdaq-mynz-mainzbiomed.png
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
October 04, 2023 08:01 ET | Mainz BioMed NV
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
nasdaq-mynz-mainzbiomed.png
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
September 27, 2023 08:01 ET | Mainz BioMed NV
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
nasdaq-mynz-mainzbiomed.png
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference 
September 20, 2023 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
nasdaq-mynz-mainzbiomed.png
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
September 13, 2023 03:01 ET | Mainz BioMed NV
Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 (GLOBE NEWSWIRE) --...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
September 05, 2023 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
August 29, 2023 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
August 22, 2023 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
August 15, 2023 03:01 ET | Mainz BioMed NV
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on Track to Report Results in September and in Q4, 2023 BERKELEY, Calif. and...